| Literature DB >> 34564146 |
Farid Menaa1, Udari Wijesinghe2, Gobika Thiripuranathar2, Norah A Althobaiti3, Aishah E Albalawi4, Barkat Ali Khan5, Bouzid Menaa1.
Abstract
Marine algae are rich in bioactive nutraceuticals (e.g., carbohydrates, proteins, minerals, fatty acids, antioxidants, and pigments). Biotic (e.g., plants, microorganisms) and abiotic factors (e.g., temperature, pH, salinity, light intensity) contribute to the production of primary and secondary metabolites by algae. Easy, profitable, and sustainable recovery methods include novel solid-liquid and liquid-liquid extraction techniques (e.g., supercritical, high pressure, microwave, ultrasound, enzymatic). The spectacular findings of algal-mediated synthesis of nanotheranostics has attracted further interest because of the availability of microalgae-based natural bioactive therapeutic compounds and the cost-effective commercialization of stable microalgal drugs. Algal extracts can serve as stabilizing/capping and reducing agents for the synthesis of thermodynamically stable nanoparticles (NPs). Different types of nanotherapeutics have been synthesized using physical, chemical, and biological methods. Marine algae are a fascinating source of lead theranostics compounds, and the development of nanotheranostics has been linked to enhanced drug efficacy and safety. Indeed, algae are remarkable nanobiofactories, and their pragmatic properties reside in their (i) ease of handling; (ii) capacity to absorb/accumulate inorganic metallic ions; (iii) cost-effectiveness; and (iv) capacity of eco-friendly, rapid, and healthier synthesis of NPs. Preclinical and clinical trials shall enable to really define effective algal-based nanotherapies. This review aims to provide an overview of the main algal compounds that are nutraceuticals and that can be extracted and purified for nanotheranostic purposes.Entities:
Keywords: alternative and complementary medicine; bioactive compounds; diabetes; innovation; marine algae; marine drugs; nanotheranostics; neurodegenerative diseases
Mesh:
Substances:
Year: 2021 PMID: 34564146 PMCID: PMC8469996 DOI: 10.3390/md19090484
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Brown-algae-derived phlorotannins and their diverse anti-diabetic effects. Adapted with permission from [128]. Copyright 2013 Elsevier.
| Phlorotannins | Anti-Diabetic Effects | Sources | References |
|---|---|---|---|
| Dieckol | α-Glucosidase inhibitor |
| [ |
| Postprandial-hyperglycemia-lowering | [ | ||
| PTP 1B inhibition | [ | ||
| Protective effect against diabetes complication | [ | ||
| Fucodiphloroethol G | α-Glucosidase inhibitor |
| [ |
| 6,6′-Bieckol | α-Glucosidase inhibitor |
| [ |
| 7-Phloroeckol | α-Glucosidase inhibitor |
| [ |
| PTP 1B inhibition | [ | ||
| Phlorofucofuroeckol A | α-Glucosidase inhibitor |
| [ |
| PTP 1B inhibition | [ | ||
| Phloroglucinol | α-Glucosidase inhibitor |
| [ |
| PTP 1B inhibition |
| [ | |
| Dioxinodehydroeckol | α-Glucosidase inhibitor |
| [ |
| PTP 1B inhibition |
| [ | |
| Diphlorethohydroxycarmalol | α-Glucosidase inhibition |
| [ |
| Postprandial-hyperglycemia-lowering | [ | ||
| Protective effect against diabetes complications | [ | ||
| Eckol | α-Glucosidase inhibitor |
| [ |
| PTP 1B inhibition |
| [ | |
| Octaphlorethol A | Glucose uptake effect in skeletal muscle |
| [ |
| Polyphenolic-rich extract | α-Glucosidase inhibitor |
| [ |
| Phlorotannin-rich extract | Postprandial hyperglycemia-lowering |
| [ |
|
| [ | ||
| Polyphenolic-rich extract | Glucose uptake in skeletal muscle |
| [ |
| Dieckol-rich extract | Improvement of insulin sensitivity |
| [ |
| Polyphenolic-rich extract | Improvement of insulin sensitivity |
| [ |
Preclinical trials with marine macroalgae-derived anti-diabetic compounds. Adapted with permission from Ref. [118]. Copyright 2018 Elsevier.
| Macroalgae | Major Compound | Effects | References |
|---|---|---|---|
|
| |||
|
| Fucosterol | Inhibition of blood glucose level and glycogen degradation | [ |
|
| Methanol extract | α-Glucosidase inhibition and suppression of postprandial hyperglycemia | [ |
|
| Polyphenols | α-Glucosidase inhibition; suppression of the increase in plasma glucose | [ |
| Phlorotannins | PTP1B and α-glucosidase inhibition | [ | |
| Fucosterol | RLAR, HRAR, PTP1B, α-glucosidase activities, and AGE formation inhibition | [ | |
|
| Dieckol | α-Glucosidase, and PTP1B | [ |
|
| Dieckol | Activation of both AMPK and Akt signal pathways; improvement of insulin sensitivity; α-Glucosidase and | [ |
|
| Phlorotannins | α-Amylase inhibition; amelioration of hyperinsulinemia | [ |
|
| Polysaccharides | Reduced fasting blood glucose; increased the levels of insulin and amylin | [ |
| Butyl-isobutyl-phthalate | α-Glucosidase inhibition | [ | |
|
| Polyphenols | α-Amylase and α-glucosidase inhibition | [ |
|
| Sargaquinoic acid | Enhances the transcriptional activities of PPARα and PPARγ | [ |
| Amelioration of insulin resistance | [ | ||
|
| Fucoidan | α- | [ |
|
| Extract | Increasing insulin sensitivity | [ |
|
| Fucoxanthin | α-Amylase and α-glucosidase inhibition, and insulin release enhancement | [ |
|
| Thunberol | PTP1B inhibition | [ |
|
| Extract | Alteration of the hepatic glucose metabolic enzyme activities and improvement of insulin resistance | [ |
|
| Fucoxanthin | HRAR, RLAR, PTP1B inhibition, and AGE formation | [ |
| Improve insulin signaling | |||
|
| Phlorotannins | Inhibition of AGEs and α-amylase | [ |
| Fucoxanthin | Inhibition of RLAR, HRAR, PTP1B activities and AGE formation | [ | |
| Fucosterol | Inhibition of RLAR, HRAR, PTP1B, α-glucosidase activities, and AGE formation | [ | |
|
| PhlorotanninsFucoidan | α-Amylase and α-glucosidase inhibition | [ |
|
| Diphlorethohydroxycarmalol | α-Amylase and α-glucosidase inhibition | [ |
| Extract | Alteraation of the hepatic glucose metabolic enzyme activities, and improvement of insulin resistance | [ | |
|
| Octaphlorethol A | Increase in GLUT4-mediated glucose utilization via activation of AMPK in muscle | [ |
|
| |||
|
| Extract | Inhibitory activity towards α-amylase | [ |
|
| Polysaccharide | Inhibitory activity towards α-glucosidase | [ |
|
| Ethanol extract | Significant decrease of plasma glucose | [ |
|
| Porphyran | Increase of adiponectin levels | [ |
|
| |||
|
| Ethanol extract | Regeneration of β-cells and/or potentiate the insulin resistance | [ |
|
| Sulfated polysaccharides | Reduce blood glucose level, and restore hepatic glycogen content | [ |
|
| Polysaccharides | α-amylase, maltase, and sucrase inhibition; Delay glucose absorption | [ |
The bromophenols from red algae as enzyme inhibitors linked to diabetes mellitus. Adapted with permission from Ref. [118]. Copyright 2018 Elsevier.
|
| 2,4,6-Tribromophenol | α-Glucosidase inhibition | [ |
| 2,4-Dibromophenol | |||
|
| 3′,5′,6′,6-Tetrabromo-2,4-dimethyldiphenyl ether | PTP1B inhibition | [ |
| 1,2,5-Tribromo-3-bromoamino-7-bromomethylnaphthalene | |||
| 2,5,8-Tribromo-3-bromoamino-7-bromomethylnaphthalene | |||
| 2,5,6-Tribromo-3-bromoamino-7-bromomethylnaphthalene | |||
| 2′,5′,6′,5,6-Pentabromo-3′,4′,3,4-tetramethoxybenzo-phenone | |||
| Bis-(2,3-dibromo-4,5-dihydroxybenzyl) ether | |||
|
| Bis-(2,3-dibromo-4,5-dihydroxybenzyl) ether | α-Glucosidase inhibition | [ |
| 2,3-Dibromo-4,5-dihydroxybenzyl alcohol | |||
| 2,3-Dibromo-4,5-dimethoxybenzyl methyl ether | |||
| 4-Bromo-2,3-dihydroxy-6-hydroxymethylphenyl | |||
| 4-Bromo-2,3-dimethoxy-6-methoxymethylphenyl | |||
| 4-Bromo-2,3-dimethoxy-6-methoxymethylphenyl | |||
| 3-Bromo-4,5-dimethoxybenzyl methyl ether | |||
|
| Bis-(2,3-dibromo-4,5-dihydroxybenzyl) ether | α-Glucosidase inhibition | [ |
| Polysiphonia morrowii | 3-Bromo-4,5-dihydroxybenzyl alcohol | α-Glucosidase inhibition | [ |
| 3-Bromo-4,5-dihydroxybenzyl methyl ether | |||
|
| Bis-(2,3-dibromo-4,5-dihydroxybenzyl) methane | Potent PTP1B inhibition | [ |
| 3-Bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)-1,2-benzene-diol | [ | ||
| 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-(isopropoxymethyl)benzyl)benzene-1,2-diol | |||
| 2,2′,3,3′-Tetrabromo-4,4′,5,5′-tetra-hydroxydiphenyl methane | [ | ||
| 2,2′,3-Tribromo-3′,4,4′,5-tetrahydroxy-6′-ethyloxy-methyldiphenyl methane | |||
|
| 2,3-Dibromo-4,5-dihydroxybenzyl methyl ether | PTP1B inhibition | [ |
| 3,5-Dibromo-4-hydroxybenzoic acid | |||
| 2,3,6-Tribromo-4,5-dihydroxymethylbenzene | |||
| 2,3,6-Tribromo-4,5-dihydroxybenzaldehyde | |||
| 2,3,6-Tribromo-4,5-dihydroxybenzyl methyl ether | |||
| Bis-(2,3,6-tribromo-4,5-dihydroxyphenyl) methane | |||
| 1,2-Bis-(2,3,6-tribromo-4,5-dihydroxyphenyl)-ethane | |||
| 1-(2,3,6-Tribromo-4,5-dihydroxybenzyl)-pyrrolidin-2-one | |||
| 2,3,6-Tribromo-4,5-dihydroxybenzyl alcohol | α-Glucosidase inhibition | [ |
Figure 1Reactive oxygen species (ROS) induce oxidative damage to lipids, proteins, and DNA. Adapted from [201].
Figure 2Alginate-derived oligosaccharide inhibits neuroinflammation. Adapted from Ref. [206].
Figure 3Natural cholinesterase inhibitors from marine algae. Adapted with permission from Ref. [210]. Copyright 2019 the Royal Society of Chemistry.
Nanoencapsulable algal compounds against neurodegenerative disorders.
| Marine Algae Species | Compounds of Interest | Model | Pharmacological Effects | References |
|---|---|---|---|---|
|
| ||||
|
| Sesquiterpene, zonarol | In vitro | Activates the Nrf2/ARE pathway, induces phase-2 enzymes, and protects neuronal cells from oxidative stress | [ |
|
| Phlorotannins | In vitro | Inhibits AChE at IC50 = 4.8 mg.mL−1 | [ |
| Suppression of BACE-1 enzyme activity at IC50 = 5.35 µM | [ | |||
| Decreased Aβ-induced cell death at IC50 = 800 µM | [ | |||
|
| Dieckol, phlorofucofuroeckol | In vivo | Improvement of memory, and possible involvement in AChE inhibition | [ |
| Triphlorethol-A | Anti-oxidative activity, scavenging activity against ROS and DPPH via activation of ERK protein | [ | ||
| Phlorotannins | In vitro | Scavenging activity against hydroxyl, superoxide, and peroxyl radicals at IC50 = 392.5, 115.2, and 128.9 µM, respectively | [ | |
| In vivo | Potentiated pentobarbital-induced sleep at >50 mg.kg−1 | [ | ||
| Neuroprotective effects against H2O2-induced oxidative stress in murine hippocampal HT22 cells at IC50 = 50 µM | [ | |||
| Phloroglucinol | In vivo | Reduces the toxicity ROS induced by hydrogen peroxide at IC50 = 10 µg.mL−1 | [ | |
| Eckol | In vitro, | Inhibits BChE IC50 = 29 µM | [ | |
| 7-phloroeckol) | In vitro, | Inhibits BChE at IC50 = 0.95 µM | [ | |
|
| Acidic oligosaccharide sugar | In vitro | Blocks the fibril formation of Aβ at IC50 = 100 µg.mL−1 | [ |
|
| Phlorotannins | In vitro | Inhibits AChE at IC50 = 62.61 to 150.80 µg.mL−1 | [ |
|
| Phlorotannins | In vitro | Inhibits AChE at IC50 = 4.89 to 42.66 µM | [ |
| Sterol (fucosterol) | In vitro | Inhibits BChE at IC50 = 421.72 µM | [ | |
|
| Fucoidan | In vitro | Blocks microglial uptake of fDNA at only 40 ng.mL−1 | [ |
| In vivo | Inhibits superoxide radicals, hydroxyl | [ | ||
| Neuroprotective through iNOS | [ | |||
| Inhibits TNF-α and IFN-γ-stimulated NO production via p38 MAPK, AP-1, JAK/STAT, and IRF-1 | [ | |||
| Inhibits beta-amyloid induced microglial clustering at IC50 = 10 µM | [ | |||
| Phlorotannins | In vivo | Suppresses the overproduction of intracellular ROS induced by hydrogen peroxide at IC50 = 0.068 mg.mL−1 | [ | |
|
| Sulfated fucans | In vitro | Prevents the accumulation of Aβ | [ |
|
| Diphlorethohydroxycarmalol (DPHC) | In vivo | Neuroprotection against hydrogen peroxide (H2O2)-induced oxidative stress in murine hippocampal neuronal cells at IC50 = 50 µM | [ |
| Phlorotannins | In vitro | Inhibits AChE at IC50 = 46.42 µM | [ | |
|
| Fucoxanthin | In vivo | Anti-oxidative activity, reduces lipid | [ |
|
| Sesquiterpenes | In vivo | Inhibiting AChE at IC50 = 65 µM | [ |
|
| Fucoidan | In vivo | Reduces the toxicity of H2O2 in PC12 cells via activation of PI3K/Akt pathway | [ |
|
| Fucoidan | In vivo | Inhibits microglia, inhibits LPS-induced NO production via suppression of p38 MAPK and ERK phosphorylation at IC50 = 125 µg.mL−1 | [ |
|
| Pheophytin A | In vivo | Produce neurite outgrowth, at IC50 = 3.9 µg.mL−1 in PC12 cells | [ |
|
| Carotenoids, sargaquinoic acid, | In vivo | Promotes neurite outgrowth activity and survival of PC-12 cells and neurite outgrowth through activation of cAMP and MAP kinase pathways at IC50 = 9 µM | [ |
|
| Plastoquinones | In vivo | Anti-oxidative activity, lipid peroxidation at IC50 = 0.95–44.3 µg.mL−1 | [ |
|
| Fucoxanthin | In vitro | Anti-oxidative activity, DPPH radical scavenging | [ |
|
| Fucoidan | In vivo | Ameliorates learning and memory deficiencies, and potential ingredient for treatment of Alzheimer’s disease | [ |
|
| Total sterols, | In vivo | Antidepressant effect | [ |
|
| Sargaquinoic acid, | In vitro | Inhibits AChE IC50 = 23.2 and 32.7 µM, respectively, inhibits BuChE at IC50 = 26 µM (for sargaquinoic acid) | [ |
|
| Meroditerpenoids | In vitro | Radical-scavenging activity as well as weak inhibitory activities against sortase A and isocitrate lyase | [ |
|
| Sulfated fucans | In vivo | Prevents the accumulation of Aβ | [ |
|
| Sulfated fucans | In vivo | Prevents the accumulation of Aβ | [ |
|
| Fucoidan | In vivo | Potential neuroprotective effects in Parkinson’s disease | [ |
|
| Glycoprotein | In vivo | AChE, BChE, and BACE1 inhibitory activities with IC50 values of 63.56, 99.03, and 73.35 µg.mL−1, respectively | [ |
|
| Spiralisone A, | In vitro | Kinases inhibitory to CDK5/p25, CK1δ, and GSK3β at IC50 = 10.0, <10 µM, and <10 µM, respectively | [ |
|
| ||||
|
| Lambda-carrageenan | In vitro | Inhibits superoxide radicals, hydroxyl radicals, and lipid peroxidation at IC50 = 0.046, 0.357, and 2.267 mg.mL−1, respectively | [ |
|
| Floridoside | In vivo | Suppresses pro- | [ |
|
| Iota-carrageenan | In vitro | Inhibits superoxide radicals, hydroxyl radicals, and lipid peroxidation at IC50 = 0.332, 0.281, and 0.830 mg.mL−1, respectively | [ |
|
| Phytol | In vitro, | Antioxidant activities at IC50 = 25–125 µg.mL−1 | [ |
|
| Kappa-carrageenan | In vitro | Inhibits superoxide radicals, hydroxyl | [ |
|
| Halogenated monoterpenes | In vitro | Inhibits AChE at IC50 = 400 µg mL−1 | [ |
| Phycoerythrobilin | In vitro | Antioxidant activity at IC50 = 0.048 mmol.g−1 | [ | |
|
| Bromophenols | In vitro | Antioxidant activity at IC50 = 5.22–23.60 µM | [ |
|
| Phenolic compounds, | In vitro | Inhibits AChE at IC50 = 0.12 mg.mL−1 | [ |
|
| ||||
|
| Bisindole alkaloid (A and B), | In vivo | Increase 5.5% of cell viability in SH-SY5Y cells, inhibits AChE at IC50 = 5.5 mg.mL−1 | [ |
|
| Phenolic compounds, | In vitro | Inhibits AChE at IC50 = 0.11 mg.mL−1 | [ |
|
| Phenolic compounds, | In vitro | Inhibits AChE at IC50 = 0.14 mg.mL−1 | [ |
|
| Clerosterol | In vivo, | Exhibits reducing activity to COX-2, iNOS, and TNF-α at IC50 = 3 µg.mL−1 | [ |
|
| Phenolic compounds, | In vitro | Inhibits AChE at IC50 = 0.07 mg.mL−1 | [ |
|
| Sulfated polysaccharides | In vitro | Scavenging activity for superoxide radicals | [ |
|
| Phenolic compounds, | In vitro | Inhibits AChE at IC50 = 0.07 mg.mL−1 | [ |
|
| Pheophorbide A | In vitro | Antioxidant activity at IC50 = 71.9 µM | [ |